Cargando…

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term treatment of cancer-associated thrombosis (CAT). Several new randomized controlled trials (RC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frere, Corinne, Farge, Dominique, Schrag, Deborah, Prata, Pedro H., Connors, Jean M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124390/ https://www.ncbi.nlm.nih.gov/pubmed/35598026 http://dx.doi.org/10.1186/s13045-022-01289-1

Ejemplares similares

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges
por: Farge, Dominique, et al.
Publicado: (2019)

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
por: Farge, Dominique, et al.
Publicado: (2022)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism
por: Smythe, Maureen A., et al.
Publicado: (2016)

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
por: Recio-Boiles, Alejandro, et al.
Publicado: (2019)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Burden of venous thromboembolism in patients with pancreatic cancer
por: Frere, Corinne
Publicado: (2021)

Management of Cancer-Associated Thrombosis: An Evolving Area
por: Frere, Corinne, et al.
Publicado: (2020)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Farge, Dominique, et al.
Publicado: (2015)

The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis
por: Frere, Corinne, et al.
Publicado: (2022)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Commentary on “Risk of venous thromboembolism after COVID‐19 vaccination”
por: Frere, Corinne, et al.
Publicado: (2022)

The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study
por: Harel, Ziv, et al.
Publicado: (2022)

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study
por: Debourdeau, Philippe, et al.
Publicado: (2017)

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants
por: Qureshi, Waqas, et al.
Publicado: (2016)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2022)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Relevance of Non-Bridging Therapy with Heparin during Temporary Interruption of Direct Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism
por: Oyakawa, Takuya, et al.
Publicado: (2022)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)
por: Farge, Dominique, et al.
Publicado: (2018)

End-of-2022 stocktake update
por: Weightman, Michael, et al.
Publicado: (2023)

Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians
por: Tun, Nay Min, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qjoob499n6n1pchqvil0op8v47